EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin
Samantha Cambier(European Organisation for Research and Treatment of Cancer), Jorg R. Oddens(Amsterdam University Medical Centers), Sandra Collette(University of Turin), Paolo Gontero(Fondazione Ricerca Molinette), George van Andel(OLVG), Levent Türkeri(Marmara University), Ziya Kırkalı(National Institute of Diabetes and Digestive and Kidney Diseases), Fernando Calais da Silva(Hospital do Desterro), Philip Powell(Freeman Hospital), Laurence Collette(GlaxoSmithKline (Belgium)), Stephen M. Prescott(MACOM (United States)), Willem Oosterlinck(Ghent University Hospital), Maurizio Brausi(De Agostini (Italy)), Richard Sylvester(European Organisation for Research and Treatment of Cancer), Wim J. Kirkels(Erasmus MC), Theo M. de Reijke(Amsterdam University Medical Centers)
Cited by 639
Related Papers
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Chemotherapy with Preoperative Radiotherapy in Rectal Cancer
|New England Journal of Medicine|2006|2.7k
Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study
|Journal of Clinical Oncology|2010|2k